MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Prasinezumab reduced progression of Parkinson’s disease motor features measured by Roche PD Mobile Application v2 sensor features: PASADENA Phase II Part 1

    K. Taylor, F. Lipsmeier, E. Volkova-Volkmar, D. Rukina, J. Anzures Cabrera, L. Essioux, M. Abt, B. van Lier, A. Thomann, H. Svoboda, W. Zago, R. Postuma, G. Pagano, M. Lindemann (Basel, Switzerland)

    Objective: To determine whether digital biomarker sensor data detect slowing in progression of core motor features of Parkinson’s disease (PD) in individuals with early PD…
  • MDS Virtual Congress 2021

    SB-0107, a drug repurposing opportunity identified through machine learning, shows the potential to treat Parkinson’s disease motor disability and levodopa-induced dyskinesia in rat and primate models

    A. Bordbar, K. Merchant, D. Weiner, M. Hill, J. Brotchie, T. Johnston, I. Famili (San Diego, USA)

    Objective: To characterize the effects of a computationally identified small molecule in rat and primate models of Parkinson’s disease-associated motor deficits and treatment-associated complications. Background:…
  • MDS Virtual Congress 2021

    Assessment of Fluctuating Parkinson’s Disease with Sensor-Based Home Monitoring-Feasibility Results

    T. Fay-Karmon, N. Galor, B. Heimler, R. Bartsch, A. Zilka, V. Livneh, M. Plotnik, S. Hassin-Baer (Ramat Gan, Israel)

    Objective: To implement home-based monitoring (HBM) using wearable devices, a smartphone dedicated app and patient reported outcomes in order to provide a more comprehensive picture…
  • MDS Virtual Congress 2021

    Istradefylline/L-DOPA combination therapy for Parkinson’s disease and blood markers of glycolytic energy homeostasis

    NAO. Kanzato, KO. Nakachi, MA. Hayashi, F. Kinjyo, W. Mizuta, SA. Mochizuki (Haebaru-Cho, Okinawa, Japan)

    Objective: To clarify the potential to preserve glycolytic energy homeostasis (GEH) with the Istradefylline combined to L-DOPA (IST-LD), and to prevent LD-induced weight loss and…
  • MDS Virtual Congress 2021

    Influence of demographic characteristics on the effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations: findings from the real-world OPTIPARK study

    B. Mohamed, A. Lees, H. Reichmann, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Cardiff, United Kingdom)

    Objective: This post-hoc analysis evaluated the influence of baseline demographic characteristics (i.e., age and gender) on the response to opicapone (OPC) in Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    Effectiveness of opicapone in Parkinson’s disease patients with motor fluctuations according to baseline use of monoamine-oxidase-B inhibitors (MAO-B) and dopamine agonists (DA): findings from the real-world OPTIPARK study

    H. Reichmann, T. Warnecke, A. Lees, D. Martins, D. Magalhães, J. Rocha, P. Soares-da-Silva (Dresden, Germany)

    Objective: This post-hoc analysis evaluated the effectiveness of opicapone (OPC) in Parkinson’s disease (PD) patients with motor fluctuations (MF) according to baseline use of monoamine-oxidase-B…
  • MDS Virtual Congress 2021

    Local Field Potentials (LFP) used to guide treatment of biphasic dyskinesias in a patient with Parkinson’s Disease (PD)

    O. Vaou, C. Harrington, S. Stanslaski, R. Cosgrove, A. Depold Hohler (Brighton, USA)

    Objective: To identify, characterize and treat dyskinesias and off time in a patient with PD via the use of gamma and beta peak LFP using…
  • MDS Virtual Congress 2021

    Laryngeal Electromyography Findings in patients with Multiple System Atrophy

    F. Gandor, A. Vogel, A. Haghikia, G. Ebersbach, T. Warnecke, D. Gruber (Beelitz-Heilstätten, Germany)

    Objective: to systematically evaluate laryngeal electromyography findings, correlate them to laryngeal movement disorders assessed by a systematic task-protocol performed during FEES and clinical laryngeal symptoms.…
  • MDS Virtual Congress 2021

    Unusual Progressive Supranuclear Palsy: a case report

    L. Megherbi, H. Si Ahmed, S. Daoudi (Tizi Ouzou, Algeria)

    Objective: Introduction: Progressive supranuclear palsy (PSP) is a rare brain condition. It is predominantly a sporadic disease that occurs between 45 and 75 years of…
  • MDS Virtual Congress 2021

    Lateralized Tau Pathology in a Case of Lewy Body Dementia with Corticobasal Syndrome

    D. Coughlin, H. Coslett, C. Mcmillan, J. Phillips, E. Lee, J. Trojanowski, M. Grossman, D. Irwin (San Diego, USA)

    Objective: To measure bilateral in vivo and postmortem tau pathology in a well-characterized patient presenting with corticobasal syndrome (CBS) due to underlying neocortical stage Lewy…
  • « Previous Page
  • 1
  • …
  • 51
  • 52
  • 53
  • 54
  • 55
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • To be or not to bupropion: a drug-induced parkinsonism?
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley